Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015479 | 0.92 | HSD17B1 (0.59) | HSD17B1HSD17B2NPC1RAB9ANFKB1 | |
| SCHEMBL21721921 | 0.91 | NPC1 (0.48) | HSD17B1HSD17B2NPC1RAB9ANFKB1 | |
| SCHEMBL23239870 | 0.91 | HSD17B1 (0.57) | HSD17B1HSD17B2LDHAKMOHPGDS | |
| SCHEMBL23956290 | 0.91 | HSD17B1 (0.57) | HSD17B1HSD17B2LDHAKMOHPGDS | |
| SCHEMBL19794434 | 0.91 | HSD17B1 (0.57) | HSD17B1HSD17B2LDHAKMOHPGDS | |
| SCHEMBL21390665 | 0.89 | KDM1A (0.44) | HSD17B1HSD17B2NPC1RAB9ANFKB1 | |
| SCHEMBL21125931 | 0.87 | HSD17B1 (0.56) | HSD17B1HSD17B2LDHAHPGDS | |
| SCHEMBL21397962 | 0.87 | NPC1 (0.44) | HSD17B1HSD17B2NPC1RAB9ANFKB1 | |
| SCHEMBL19794370 | 0.85 | LDHA (0.50) | HSD17B1HSD17B2NPC1RAB9ANFKB1 | |
| SCHEMBL19794431 | 0.85 | LDHA (0.50) | HSD17B1HSD17B2NPC1RAB9ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-20210111345-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2021-04-15 | — | — | US | disclosed |
| WO-2019179909-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210111345-A1 | METAL COMPLEXES | NCLN, BICRA, AP3M1 | HSD17B1 4561/4885HSD17B2 4525/4885NPC1 3661/4885 |
| US-11917903-B2 | Metal complexes | NCLN, BICRA, AP3M1 | HSD17B1 4561/4885HSD17B2 4525/4885NPC1 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.